Blood flow-metabolic relationships are dependent on tumour size in non-small cell lung cancer: a study using quantitative contrast-enhanced computer tomography and positron emission tomography

被引:73
|
作者
Miles, KA [1 ]
Griffiths, MR
Keith, CJ
机构
[1] Univ Sussex, Brighton & Sussex Med Sch, Div Clin & Lab Sci, Brighton BN7 3PB, E Sussex, England
[2] Queensland Univ Technol, Gardens Point Brisbane, Brisbane, Qld, Australia
[3] Wesley Res Inst, Brisbane, Qld, Australia
关键词
non-small cell lung cancer; tumour blood flow; glucose metabolism; tumour size; F-18-FDG;
D O I
10.1007/s00259-005-1932-7
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
Purpose: The purpose of this study was to undertake dual assessment of tumour blood flow and glucose metabolism in non-small cell lung cancer (NSCLC) using contrast-enhanced computed tomography (CE-CT) and F-18-fluorodeoxyglucose positron emission tomography (FDG-PET) in order to assess how the relationships between these parameters vary with tumour size and stage. Methods: Tumour blood flow and glucose metabolism were assessed in 18 NSCLCs using quantitative CE-CT and FDG-PET respectively. Contrast enhancement and FDG uptake were both normalised to injected dose and patient weight to yield correspondingly the standardised perfusion value (SPV) and standardised uptake value (SUV). Tumour area was measured from conventional CT images. Results: The ratio of SUV to SVP and the metabolic - flow difference ( SUV - SVP) correlated with tumour size ( r= 0.56, p= 0.015 and r= 0.60 and p= 0.008 respectively). A metabolic flow difference of greater than 4 was more common amongst tumours of stages III and IV ( odds ratio 10.5; 95% confidence limits 0.24 - 32.1). A significant correlation between SUV and SPV was found only for tumours smaller than 4.5 cm(2) ( r= 0.85, p= 0.03). Conclusion: Blood flow - metabolic relationships are not consistent in NSCLC but depend upon tumour size and stage. Quantitative CE-CT as an adjunct to an FDG study undertaken using integrated PET-CT offers an efficient way to augment the assessment of tumour biology with possible future application as part of clinical care.
引用
收藏
页码:22 / 28
页数:7
相关论文
共 50 条
  • [31] Prognostic value of metabolic tumor parameters in pretreatment 18F-fluorodeoxyglucose positron emission tomography-computed tomography scan in advanced non-small cell lung cancer
    Mallick, Ayan
    Das, Jayanta
    Shaw, Manoj Kumar
    Biswas, Bivas
    Ray, Soumendranath
    INDIAN JOURNAL OF NUCLEAR MEDICINE, 2021, 36 (02): : 107 - 113
  • [32] Combination of Circulating Cell-Free DNA and Positron Emission Tomography to Distinguish Non-Small Cell Lung Cancer from Tuberculosis
    Zheng, Wenqiang
    Quan, Bin
    Gao, Guangjian
    Zhang, Puhong
    Huang, Lizhu
    LABORATORY MEDICINE, 2023, 54 (02) : 130 - 141
  • [33] Whole body 18F-2-deoxyglucose positron emission tomography to restage non-small cell lung cancer
    Changlai, SP
    Tsai, SC
    Chou, MC
    Ho, YJ
    Kao, CH
    ONCOLOGY REPORTS, 2001, 8 (02) : 337 - 339
  • [34] The value of 18F-fluorodeoxyglucose positron emission tomography-based radiomics in non-small cell lung cancer
    Chen, Yu-Hung
    Lue, Kun-Han
    Chu, Sung-Chao
    Lin, Chih-Bin
    Liu, Shu-Hsin
    TZU CHI MEDICAL JOURNAL, 2025, 37 (01): : 17 - 27
  • [35] Pattern and Predictors of False Positive Lymph Node Involvement on Positron Emission Tomography in Patients with Non-Small Cell Lung Cancer
    Tamura, Masaya
    Oda, Makoto
    Matsumoto, Isao
    Waseda, Ryuichi
    Watanabe, Go
    THORACIC AND CARDIOVASCULAR SURGEON, 2012, 60 (02) : 105 - 110
  • [36] Can positron emission tomography assessment of response to treatment help to individualize use of erlotinib in non-small cell lung cancer?
    Hureaux, J.
    Couturier, O.
    Lacoeuille, F.
    Bouchet, F.
    Chouaid, C.
    Saulnier, P.
    Urban, T.
    REVUE DES MALADIES RESPIRATOIRES, 2016, 33 (09) : 817 - 823
  • [37] Determination of the prognostic value of [18F]fluorodeoxyglucose uptake by using positron emission tomography in patients with non-small cell lung cancer
    Jeong, HJ
    Min, JJ
    Park, JM
    Chung, JK
    Kim, BT
    Jeong, JM
    Lee, DS
    Lee, MC
    Han, SK
    Shim, YS
    NUCLEAR MEDICINE COMMUNICATIONS, 2002, 23 (09) : 865 - 870
  • [38] Correlations between contrast-enhanced ultrasound and microvessel density in non-small cell lung cancer: A prospective study
    Chen, Wuxi
    Zhang, Yuxin
    Tang, Jiaxin
    Wei, Dongjun
    Liao, Haixing
    Zhang, Shiyu
    He, Liantu
    Tang, Qing
    FRONTIERS IN ONCOLOGY, 2023, 13
  • [39] Mesorectal thromboembolism with increased 18F-fluorodeoxyglucose uptake during positron emission tomography/computed tomography in a patient with non-small cell lung cancer
    Sato, Yoshihiro
    Tsujinaka, Shingo
    Miura, Tomoya
    Kitamura, Yoh
    Sawada, Kentaro
    Mitamura, Atsushi
    Yamamoto, Kuniharu
    Nakano, Toru
    Katayose, Yu
    Shibata, Chikashi
    JOURNAL OF SURGICAL CASE REPORTS, 2024, 2024 (07):
  • [40] OCCULT NODAL METASTASIS IN POSITRON EMISSION TOMOGRAPHY AND COMPUTED TOMOGRAPHY DIAGNOSED STAGE I NON-SMALL CELL LUNG CANCER: A POOLED ANALYSIS OF MULTICENTER STUDIES
    Wang, Jingbo
    Wang, Luhua
    Kong, Feng-Ming
    JOURNAL OF THORACIC ONCOLOGY, 2011, 6 (06) : S525 - S526